Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 314

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction

Kastrati, Adnan, Neumann, Franz-Josef, Schulz, Stefanie, Massberg, Steffen, Byrne, Robert A., Ferenc, Miroslaw, Laugwitz, Karl-Ludwig, Pache, Jürgen, Ott, Ilka, Hausleiter, Jörg, Seyfarth, Melchior, Gick, Michael, Antoniucci, David, Schömig, Albert, Berger, Peter B., Mehilli, Julinda·2011·New England Journal of Medicine

Abstract

BACKGROUND: The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). We compared the two treatments in this patient population. METHODS: Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). The study tested the hypothesis that abciximab and heparin would be superior to bivalirudin with respect to the primary composite end point of death, large recurrent myocardial infarction, urgent target-vessel revascularization, or major bleeding within 30 days. Secondary end points included the composite of death, any recurrent myocardial infarction, or urgent target-vessel revascularization (efficacy end point) and major bleeding (safety end point) within 30 days. RESULTS: The primary end point occurred in 10.9% of the patients in the abciximab group (94 patients) and in 11.0% in the bivalirudin group (95 patients) (relative risk with abciximab, 0.99; 95% confidence interval [CI], 0.74 to 1.32; P=0.94). Death, any recurrent myocardial infarction, or urgent target-vessel revascularization occurred in 12.8% of the patients in the abciximab group (110 patients) and in 13.4% in the bivalirudin group (115 patients) (relative risk, 0.96; 95% CI, 0.74 to 1.25; P=0.76). Major bleeding occurred in 4.6% of the patients in the abciximab group (40 patients) as compared with 2.6% in the bivalirudin group (22 patients) (relative risk, 1.84; 95% CI, 1.10 to 3.07; P=0.02). CONCLUSIONS: Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non-ST-segment elevation myocardial infarction who were undergoing PCI. (Funded by Nycomed Pharma and others; ISAR-REACT 4 ClinicalTrials.gov number, NCT00373451.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1109596

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 314

Metadata

Authors
Kastrati, A., Neumann, F.-J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., Laugwitz, K.-L., Pache, J., Ott, I., Hausleiter, J., Seyfarth, M., Gick, M., Antoniucci, D., Schömig, A., Berger, P. B., & Mehilli, J.
Venue
New England Journal of Medicine
Published
2011-11-24
Volume
365
Issue
21
Pages
1980-1989
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2073159589
Cited by
314
References
19
FWCI
24.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. https://app.cochat.ai/papers/10.1056/nejmoa1109596
The paper
Kastrati, A., Neumann, F.-J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., Laugwitz, K.-L., Pache, J., Ott, I., Hausleiter, J., Seyfarth, M., Gick, M., Antoniucci, D., Schömig, A., Berger, P. B., & Mehilli, J. (2011). Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1109596

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.